2. Search Result
Search Result
Pathways Recommended: JAK/STAT Signaling
Results for "

STAT/TET1 axis

" in MedChemExpress (MCE) Product Catalog:

755

Inhibitors & Agonists

1

Screening Libraries

2

Fluorescent Dye

3

Biochemical Assay Reagents

44

Peptides

16

Inhibitory Antibodies

195

Natural
Products

16

Recombinant Proteins

35

Isotope-Labeled Compounds

46

Antibodies

4

Click Chemistry

35

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-160638
    NSC-311068

    		TET Protein Cancer
    NSC-311068 is TET1 inhibitor. NSC-311068 selectively suppress TET1 transcription and 5-hydroxymethylcytosine (5hmC) modification. NSC-311068 represses the level of TET1 expression and the global 5hmC level. NSC-311068 effectively inhibits cell viability in AML cells with high expression of TET1 [1].
    NSC-311068
  • HY-122258
    NSC-370284

    		STAT TET Protein Cancer
    NSC-370284 is a selective inhibitor of ten-eleven translocation 1 (TET1) and 5-hydroxymethylcytosine (5hmC). NSC-370284 significantly inhibits the level of TET1 expression via targets STAT3/5 [1].
    NSC-370284
  • HY-111558
    Bobcat339
    15+ Cited Publications

    		 DNA Methyltransferase TET Protein Cancer
    Bobcat339 is a potent and selective cytosine-based inhibitor of TET enzyme, with IC50s of 33 μM and 73 μM for TET1 and TET2, respectively. Bobcat339 is useful to the field of epigenetics and serves as a starting point for new therapeutics that target DNA methylation and gene transcription [1].
    Bobcat339
  • HY-120395
    UC-514321
    1 Publications Verification

    		 STAT Apoptosis TET Protein Inflammation/Immunology Cancer
    UC-514321, a structural analog of NSC370284 with higher activity, directly targets STAT3/5 and represses TET1 expression, but not TET2 or TET3. UC-514321 has the potential to treat acute myeloid leukemia (AML) both in vitro and in vivo, with low toxicity [1].
    UC-514321
  • HY-111558A
    Bobcat339 hydrochloride
    15+ Cited Publications

    		 DNA Methyltransferase TET Protein Cancer
    Bobcat339 hydrochloride is a potent and selective cytosine-based inhibitor of TET enzyme, with the IC50s of 33 μM and 73 μM for TET1 and TET2, respectively. Bobcat339 hydrochloride is useful to the field of epigenetics and serves as a starting point for new therapeutics that target DNA methylation and gene transcription [1].
    Bobcat339 hydrochloride
  • HY-P11094
    Tet1

    		TET Protein Neurological Disease
    Tet1 is a peptide with the sequence of HLNILSTLWKYRC. Tet1 can specifically bind to the neuronal ganglioside receptor GT1b and possesses neuronal targeting ability. Tet1 can be used in research related to drug delivery [1].
    Tet1
  • HY-P10998
    Tet1 peptide

    		TET Protein Neurological Disease
    Tet1 peptide is neuron-specific ligand for GT1B gangliosides. Tet1 peptide can be used as a ligand for targeted delivery of functionalized polymersomes [1] .
    Tet1 peptide
  • HY-RS14384
    TET1 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    TET1 Human Pre-designed siRNA Set A contains three designed siRNAs for TET1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    TET1 Human Pre-designed siRNA Set A
    TET1 Human Pre-designed siRNA Set A
  • HY-RS23219
    Tet1 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Tet1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Tet1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Tet1 Rat Pre-designed siRNA Set A
    Tet1 Rat Pre-designed siRNA Set A
  • HY-RS16779
    Tet1 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Tet1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Tet1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Tet1 Mouse Pre-designed siRNA Set A
    Tet1 Mouse Pre-designed siRNA Set A
  • HY-W018324
    5-Hydroxymethylcytosine

    5hmC

    		 Endogenous Metabolite Neurological Disease Metabolic Disease Cancer
    5-Hydroxymethylcytosine (5hmC) is an oxidized forms of 5-methylcytosine (5mC) in mammalian DNA. 5-Hydroxymethylcytosine is produced from 5mC in an enzymatic pathway involving three 5mC oxidases, Ten-eleven translocation (TET)1, TET2, and TET3. The conversion of 5mC into 5hmC can be the first step in a pathway leading towards DNA demethylation. 5-Hydroxymethylcytosine is associated with gene transcription and frequently used as a mark to investigate dynamic DNA methylation conversion during mammalian development. 5-Hydroxymethylcytosine can be used for the study of non-small cell lung cancer (NSCLC), neurodegenerative diseases (Alzheimer’s, Parkinson’s) and hematological malignancies (acute myeloid leukemia, myelodysplastic syndromes) [1] .
    5-Hydroxymethylcytosine
  • HY-W396714
    Succinic acid sodium

    Wormwood acid sodium

    		 Potassium Channel TET Protein Cardiovascular Disease Neurological Disease
    Succinic acid sodium is a potent and orally active anxiolytic agent. Succinic acid sodium shows inhibitory effects on colonic epithelial cell proliferation in vivo. Succinic acid sodium can down-regulate the expression of KCNMB1 (potassium channel subunit β1) and TET1 (ten?eleven translocation 1). Succinic acid sodium can be used for gestational hypertension research [1] .
    Succinic acid sodium
  • HY-402410
    TETi76
    1 Publications Verification

    		 TET Protein Cancer
    TETi76 is an orally active TET family inhibitor with IC50 values ??of 1.5, 9.4 and 8.8 μM for TET1, TET2 and TET3, respectively. TETi76 competitively binds to the active site of TET enzymes, reduces cytosine hydroxymethylation and restricts clonal growth of TET2 mutants in vitro and in vivo, but does not affect the growth of normal hematopoietic precursor cells. TETi76 can be used for leukemia research [1].
    TETi76
  • HY-12303
    OAC1
    1 Publications Verification

    		 Oct3/4 TET Protein Cancer
    OAC1 is a potent Oct4 activator. OAC1 activates Oct4 and Nanog promoters and enhances induced pluripotent stem cells (iPSC) formation. OAC1 activates OCT4 through upregulation of HOXB4 expression. OAC1 increases transcription of the Oct4-Nanog-Sox2 triad and TET1. OAC1 facilitates the reprogramming of cells by enhancing efficiency and shortening the reprogramming time [1] .
    OAC1
  • HY-128450
    JAK-STAT-IN-1

    		JAK STAT Inflammation/Immunology Cancer
    JAK-STAT-IN-1 (compound 1) is a selective JAK-STAT inhibitor. JAK-STAT-IN-1 can be used for the research of autoimmune disorder [1].
    JAK-STAT-IN-1
  • HY-150538
    STAT3-IN-12
    1 Publications Verification

    		 STAT Apoptosis Cancer
    STAT3-IN-12 is a potent STAT3 signal inhibitor that can inhibit IL-6 induced JAK/STAT3 signalling pathway activation. STAT3-IN-12 inhibits cancer cell growth, migration, and induce cell apoptosis as well as cycle arrest. STAT3-IN-12 can be used in cancer-related research, such as hepatocellular carcinoma (HCC) and oesophageal carcinoma [1].
    STAT3-IN-12
  • HY-W018324S
    5-Hydroxymethylcytosine-13C,d2

    5hmC-13C,d2

    		 Isotope-Labeled Compounds Neurological Disease
    5-Hydroxymethylcytosine- 13C,d2 is the 13C and deuterium labeled 5-Hydroxymethylcytosine (HY-W018324). 5-Hydroxymethylcytosine (5hmC) is an oxidized forms of 5-methylcytosine (5mC) in mammalian DNA. 5-Hydroxymethylcytosine is produced from 5mC in an enzymatic pathway involving three 5mC oxidases, Ten-eleven translocation (TET)1, TET2, and TET3. The conversion of 5mC into 5hmC can be the first step in a pathway leading towards DNA demethylation. 5-Hydroxymethylcytosine is associated with gene transcription and frequently used as a mark to investigate dynamic DNA methylation conversion during mammalian development. 5-Hydroxymethylcytosine can be used for the study of non-small cell lung cancer (NSCLC), neurodegenerative diseases (Alzheimer’s, Parkinson’s) and hematological malignancies (acute myeloid leukemia, myelodysplastic syndromes) [1] .
    5-Hydroxymethylcytosine-13C,d2
  • HY-112447
    STAT3-IN-5

    		STAT Cancer
    STAT3-IN-5 is a potent STAT3 inhibitor. STAT3-IN-5 inhibits STAT3-Y705 phosphorylation with an EC50 value of 170 nM. STAT3-IN-5 inhibits cytokine induced JAK activation. STAT3-IN-5 induces apoptosis. STAT3-IN-5 can be used in research of cancer [1].
    STAT3-IN-5
  • HY-P10115
    APT STAT3

    		STAT Cancer
    APT STAT3 is a specific STAT3-binding peptide. APT STAT3 can bind STAT3 with high specificity and affinity (～231 nmol/L). APT STAT3 is a tractable agent for translation to target the broad array of cancers harboring constitutively activated STAT3 [1].
    APT STAT3
  • HY-P10114
    STAT3-IN-24, cell-permeable

    PpYLKTK-mts; STAT3 PI

    		 STAT Cancer
    STAT3-IN-24, cell-permeable (PpYLKTK-mts) is a STAT3 peptide inhibitor. STAT3-IN-24, cell-permeable inhibits recruitment of STAT3 to Jak2 and phosphorylation of Y705, thus preventing the dimerization and the nuclear translocation of STAT3 [1].
    STAT3-IN-24, cell-permeable
  • HY-150603
    STAT3-IN-13

    		STAT Apoptosis Bcl-2 Family Cancer
    STAT3-IN-13 (compound 6f) is a potent STAT3 inhibitor. STAT3-IN-13 has anti-proliferative effects and binds to the STAT3 SH2 domain with a KD of 0.46 μM. STAT3-IN-13 inhibits the phosphorylation of STAT3 Y705 and downstream target gene expression. STAT3-IN-13 induces apoptosis in vitro and suppresses the growth and metastasis of tumor in vivo. STAT3-IN-13 can be used for cancer research [1].
    STAT3-IN-13
  • HY-N10472
    STAT3-IN-14

    		STAT Cancer
    STAT3-IN-14 (Compound 1) is a STAT3 inhibitor and has STAT3 phosphorylation inhibitory activity. STAT3-IN-14 (Compound 1) can directly bind to the hinge region of STAT3 [1].
    STAT3-IN-14
  • HY-146666
    STAT3-IN-9

    		Apoptosis STAT Cancer
    STAT3-IN-9 is a potent STAT3 inhibitor. STAT3-IN-9 inhibits the activation of STAT3 (Tyr705) without influencing the phosphorylation of STAT1 (Tyr701). STAT3-IN-9 induces apoptosis and cell cycle arrest at the G2/M phase [1].
    STAT3-IN-9
  • HY-W1113771
    STAT6-IN-7

    		STAT Interleukin Related Inflammation/Immunology
    STAT6-IN-7 (Compound 178) is a STAT6 inhibitor. STAT6-IN-7 has an IC50 value for inhibiting the binding of human STAT6/pIL-4Rα of 0.28 μM. STAT6-IN-7 can be used in the research of inflammatory and allergic diseases [1].
    STAT6-IN-7
  • HY-162607
    STAT3-IN-28

    		STAT Inflammation/Immunology
    STAT3-IN-28 (compound 18) is a STAT3 inhibitor. STAT3-IN-28 can inhibit the activation of microglia and has anti-neuroinflammatory effects. STAT3-IN-28 can cross the blood-brain barrier [1].
    STAT3-IN-28
  • HY-128588
    STAT3-IN-3
    5+ Cited Publications

    		 STAT Apoptosis Cancer
    STAT3-IN-3 is a potent and selective inhibitor of signal transducer and activator of transcription 3 (STAT3), with anti-proliferative activity. STAT3-IN-3 induces apoptosis in breast cancer cells. STAT3-IN-3 acts as a promising mitochondria-targeting STAT3 inhibitor for cancer research [1].
    STAT3-IN-3
  • HY-144871
    STAT3-IN-8

    		STAT Cancer
    STAT3-IN-8 (compound H172) is a potent STAT3 inhibitor. STAT3-IN-8 has the potential for cancer research [1].
    STAT3-IN-8
  • HY-155982
    STAT3-IN-20

    		STAT Cancer
    STAT3-IN-20 (Compound 40) is a selective STAT3 inhibitor (IC50: 0.65 μM). STAT3-IN-20 binds the SH2 domain to inhibit STAT3 phosphorylation, translocation, and downstream gene transcription. STAT3-IN-20 exhibits antiproliferative activities against STAT3-overactivated DU145 and MDA-MB-231 cancer cells (IC50: 2.97 μM and 3.26 μM respectively). STAT3-IN-20 induces cell cycle arrest and apoptosis [1].
    STAT3-IN-20
  • HY-101853
    STAT5-IN-1
    25+ Cited Publications

    		 STAT Cancer
    STAT5-IN-1 is a STAT5 inhibitor with an IC50 of 47 μM for STAT5β isoform.
    STAT5-IN-1
  • HY-153991
    STAT6-IN-2

    		STAT Inflammation/Immunology
    STAT6-IN-2 (Compound R-84) is a STAT6 inhibitor that can inhibit the tyrosine phosphorylation of STAT6. STAT6-IN-2 can also inhibit the secretion of eotaxin-3. STAT6-IN-2 can be used in the research of immune diseases and allergic inflammatory diseases such as asthma [1].
    STAT6-IN-2
  • HY-146728
    STAT3-IN-10

    		STAT Apoptosis Cancer
    STAT3-IN-10 is a STAT3 inhibitor with an IC50 value of 5.18 µM. STAT3-IN-10 directly binds to STAT3 SH2 domain, induces cancer cells apoptosis [1].
    STAT3-IN-10
  • HY-169797
    STAT3-IN-38

    		STAT Survivin Apoptosis Cancer
    STAT3-IN-38 (Compound 4m) is an inhibitor of STAT3 (KD of rhSTAT3: 45.33  µM). STAT3-IN-38 binds to the SH2 domain of STAT3 protein and suppresses the STAT3’s phosphorylation at site pTyr705 as well as its downstream genes (Survivin and Mcl-1). STAT3-IN-38 could block cell-cycle and induce Apoptosis in colorectal cancer cells [1].
    STAT3-IN-38
  • HY-170837
    STAT5-IN-3

    		STAT Cancer
    STAT5-IN-3 (Compound 14a) is a STAT5 inhibitor with anticancer activity. STAT5-IN-3 blocks the tyrosine phosphorylation of STAT5A/5B at the Y694/699 sites and significantly reduces the expression of STAT5B protein, thereby inhibiting downstream gene transcription and blocking the proliferation and survival of leukemia cells. Additionally, STAT5-IN-3 holds significant value in overcoming chemotherapy resistance [1].
    STAT5-IN-3
  • HY-168043
    STAT3-IN-35

    		STAT Cancer
    STAT3-IN-35 is a STAT3 inhibitor that binds to SH2 domain. STAT3-IN-35 inhibits the phosphorylation of STAT3 and possesses antiproliferative activities against triple-negative breast cancer (TNBC) cell lines. STAT3-IN-35 also has a toxicity and potent antitumor activity in a TNBC xenograft model [1].
    STAT3-IN-35
  • HY-168903
    STAT3-IN-41

    		STAT Cancer
    STAT3-IN-41 (Compound 16) is a prodrug of compound 1. STAT3-IN-41 slowly releases compound 1 inhibiting STAT3 signaling pathway. STAT3-IN-41 shows antitumor activity against lung cancer, hepatocellular carcinoma and pancreatic cancer [1].
    STAT3-IN-41
  • HY-151976
    STAT3-IN-15
    1 Publications Verification

    		 STAT Inflammation/Immunology
    STAT3-IN-15 is a potent and orally active STAT3 inhibitor against idiopathic pulmonary fibrosis (IPF). STAT3-IN-15 inhibits STAT3 phosphorylation. STAT3-IN-15 also inhibits the migration and deformation of epithelial cells induced by TGF-β1 and inhibit epithelial-mesenchymal transition (EMT) [1].
    STAT3-IN-15
  • HY-102048
    STAT5-IN-2
    2 Publications Verification

    		 STAT Apoptosis Cancer
    STAT5-IN-2 is a STAT5 inhibitor, extracted from reference 1, example 17f. STAT5-IN-2 has potent antileukemic effect [1].
    STAT5-IN-2
  • HY-155808
    STAT3-IN-18

    		STAT JAK Apoptosis COX Cancer
    STAT3-IN-18 (compound SPP) is a platinum (IV) complex with an axial ligand derived from sandalwood. STAT3-IN-18 inhibits the JAK2-STAT3 pathway in breast cancer (BC) cells, with anti-proliferative activity. STAT3-IN-18 activates caspase-3 and increases cleaved polyADP-ribose polymerase to induce apoptosis. STAT3-IN-18 promotes maturation and antigen presentation of dendritic cells and demonstrates safety in vivo.
    STAT3-IN-18
  • HY-149007
    STAT3-IN-11
    1 Publications Verification

    		 STAT Apoptosis Cancer
    STAT3-IN-11 (7a) is a selective STAT3 inhibitor that inhibits the phosphorylation of STAT3 at site pTyr705. STAT3-IN-11 inhibits the phosphorylation of downstream genes (Survivin and Mcl-1) without affecting its upstream tyrosine kinases (Src and JAK2) levels and p-STAT1 expression. STAT3-IN-11 can induce cancer cell apoptosis, which is potential for the discovery of effective STAT3 inhibitors and antitumor agents against cancers [1].
    STAT3-IN-11
  • HY-153992
    STAT6-IN-3
    1 Publications Verification

    		 STAT Inflammation/Immunology
    STAT6-IN-3 is a phosphopeptide mimic targeting the SH2 domain of STAT6 and has a high affinity for STAT6 (IC50: 0.04 μM). STAT6-IN-3 can be used in the research of inflammation such as asthma [1].
    STAT6-IN-3
  • HY-158398
    STAT6-IN-4

    		STAT Inflammation/Immunology
    STAT6-IN-4 (Ex. 78) is a STAT6 inhibitor, with an IC50 of 0.34 μM. STAT6-IN-4 can be used in the research of diseases such as inflammatory and allergic diseases [1].
    STAT6-IN-4
  • HY-161644
    STAT3-IN-27

    		STAT Apoptosis Cancer
    STAT3-IN-27 (Compound 41) is an orally active inhibitor for phosphorylation of STAT3 (KD is 4.4 μM) and STAT3 transcription (IC50 is 22.57 nM). STAT3-IN-27 inhibits proliferation of various cancer cells with IC50 of 10-500 nM. STAT3-IN-27 arrests the cell cycle at G2/M phase, induces mitochondrial dysfunction and apoptosis in HCT116, inhibits cell migration of HCT116. STAT3-IN-27 exhibits antitumor efficacy in mouse model [1].
    STAT3-IN-27
  • HY-175010
    STAT3-IN-44

    		STAT Apoptosis Bcl-2 Family Caspase Cancer
    STAT3-IN-44 is a potent STAT3 inhibitor with IC50s of 1.84 (C6 cells) and 4.81 μM (A549 cells). STAT3-IN-44 inhibits STAT3 phosphorylation, downregulates Bcl-2, and upregulates Caspase-3 to promote late-stage apoptosis. STAT3-IN-44 significantly suppresses tumor cell proliferation and migration. STAT3-IN-44 can be used for the study of cancers such as glioma and lung cancer [1].
    STAT3-IN-44
  • HY-144870
    STAT3-IN-7

    		STAT Cancer
    STAT3-IN-7, an aryl sulfonamido azetidine compound, is an orally active STAT3 inhibitor. STAT3-IN-7 has anticancer activities (WO2021016333A1, H182) [1].
    STAT3-IN-7
  • HY-169007
    STAT3-IN-34

    		STAT Inflammation/Immunology
    STAT3-IN-34 (Compound 15E) is an inhibitor for STAT3, and inhibits the nuclear translocation and transcriptional regulator activity of STAT3. STAT3-IN-34 inhibits the proliferation of cell HaCaT with IC50 of 0.008 μM. STAT3-IN-34 inhibits IL-17A expression and ameliorates Imiquimod (HY-B0180)-induced psoriasis in mice [1].
    STAT3-IN-34
  • HY-P10113
    STAT3-IN-23

    		STAT Cancer
    STAT3-IN-23 (PY*LKTK) is a potent STAT3 inhibitor [1].
    STAT3-IN-23
  • HY-168519
    STAT3-IN-36

    		STAT Cancer
    STAT3-IN-36 (compound 11g) is a triple-target inhibitor targeting LRPPRC, STAT3, and CDK1 with anticancer activity. STAT3-IN-36 binds to LRPPRC, STAT3, and CDK1, exerting a stronger anticancer effect than TMF (HY-N6818) or Capecitabine (HY-B0016). STAT3-IN-36 inhibits HGC27 cells with IC50 1.8 μM. [1].
    STAT3-IN-36
  • HY-160496
    STAT3-IN-25

    		STAT Cancer
    STAT3-IN-25 (Compound 2p) is a potent STAT3 inhibitor with a p-trifluoroethoxy benzyl substituent. STAT3-IN-25 shows STAT3 luciferase inhibition activity using HEK293T cells with an IC50 of 22.3 nM and ATP production inhibition activity using BxPC-3 cells with an IC50 of 32.5 nM. STAT3-IN-25 has the potential for pancreatic cancer research [1].
    STAT3-IN-25
  • HY-148706
    STAT3-IN-17

    		STAT Infection Cancer
    STAT3-IN-17 is a moderate STAT3 inhibitor (IC50=0.7 μM; HEK-Blue IL-6), with antiproliferative activity in HeLa cells. STAT3-IN-17 has good pharmacokinetic characteristics. STAT3-IN-17 also inhibits pyruvate-ferredoxin oxidoreductase (PFOR), and inhibits Helicobacter pylori [1] .
    STAT3-IN-17
  • HY-173000
    STAT3-IN-40

    		Apoptosis Ferroptosis STAT Cancer
    STAT3-IN-40 (Compound 8b) is an anti-cancer agent. STAT3-IN-40 can trigger the immune responses of CD4+ and CD8+ T lymphocytes and induce ferroptosis and apoptosis of tumor cells by inhibiting the expression and phosphorylation of STAT3. STAT3-IN-40 can be used in the research of chemoimmunotherapeutic agents for cancer [1].
    STAT3-IN-40

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: